Do Inhaled Corticosteroids Cause an Increased Risk for Developing or Worsening a Patient’s Diabetes Mellitus? by Luttjohann, Jarrod R
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2012
Do Inhaled Corticosteroids Cause an Increased
Risk for Developing or Worsening a Patient’s
Diabetes Mellitus?
Jarrod R. Luttjohann
Philadelphia College of Osteopathic Medicine, jarrodlu@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Luttjohann, Jarrod R., "Do Inhaled Corticosteroids Cause an Increased Risk for Developing or Worsening a Patient’s Diabetes
Mellitus?" (2012). PCOM Physician Assistant Studies Student Scholarship. Paper 55.
Do inhaled corticosteroids cause an increased risk for developing or 
worsening a patient’s diabetes mellitus? 
 
 
 
 
 
 
Jarrod R. Luttjohann, PA-S 
 
 
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
 
In Partial Fulfillment of the Requirements For 
 
The Degree of Master of Science 
 
In 
 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 
 
 
December 16, 2011 
ABSTRACT 
 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not inhaled corticosteroids 
(ICS) cause an increased risk for developing or worsening a patient’s diabetes mellitus (DM). 
 
STUDY DESIGN 
Review of three English language primary studies published in 1993, 2009 and 2010. 
 
DATA SOURCES 
A nested case-control analysis, a randomized control trial and a prospective randomized, double-
blind, double-dummy, placebo-controlled, crossover investigation comparing the onset and/or 
progression of diabetes mellitus in patients using ICS were found using Ovid MEDLINE, 
PubMed, and Cochrane databases. 
 
OUTCOMES MEASURED 
Incidence or progression of diabetes was measured using a combination of oral glucose tolerance 
test, serum insulin levels, HGbA1c levels, and fasting glucose levels. 
 
RESULTS  
Faul had 70% of patients that experienced some increase in HGbA1c levels, but none that were 
statistically significant. Kiviranta had very slight increases in blood glucose when compared to 
the patient’s baseline measurements. Suissa had a 34% increase in the onset or progression to 
insulin use of diabetic patients. 
 
CONCLUSIONS 
While all of the studies showed an increase in the incidence or progression of diabetes in patients 
taking ICS, none of the increases were significant enough to preclude diabetics from taking ICS 
as needed. Careful monitoring of a patient with diabetes needing an ICS is warranted to prevent 
loss of diabetes control. Additionally, a baseline HGbA1c level on a patient newly prescribed an 
ICS might be beneficial. 
 
KEYWORDS 
Inhaled corticosteroids, diabetes 
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INTRODUCTION 
According to Faul et al, the prevalence of Diabetes Mellitus (DM), chronic obstructive 
pulmonary disease (COPD), and asthma are increasing.1(p14) These last two conditions, along 
with others, require the use of inhaled corticosteroids (ICS). With these two facts in mind, the 
likelihood that a person will be given an inhaled corticosteroid while being at risk for, or having, 
DM increases at the same rate. A link between ICS use and DM incidence or progression could 
have vast, yet currently unrealized, implications, as this situation, where a patient needs an ICS 
and has, or is at risk for developing DM, becomes more and more common. It is likely that it will 
become vital for both patients and Physician Assistants to be familiar with the effects of ICS on 
blood glucose level control as it relates to DM prevention and treatment.  
15% of adults have a condition, such as COPD or asthma, requiring ICS as treatment.2 
25.8 million, or 8.3%, of people in the US have DM.3 DM is a very costly disease with the most 
recent data from the CDC showing costs to the US of $174 billion dollars for healthcare related 
to DM.3 While a firm number of visits to healthcare providers is hard to establish, $116 billion 
dollars were spent on direct medical costs of the above $174 billion. Also, people with DM spent 
2.3 times more on healthcare in 2007 than people without diabetes when variability between 
different ages and sexes are taken into account.3 DM has a very real impact on the time patients 
spend seeking healthcare and how much money they have to spend on that care. 
Usually, to treat DM, there are several options used: insulin, sulfonylureas, meglitinides, 
biguanides, thiazolidinediones, α-glucosidase inhibitors, or DPP-4 inhibitors. To treat asthma or 
COPD, there are several inhaled corticosteroids available including flunisolide, triamcinolone 
acetonide, beclomethasone dipropionate, fluticasone propionate, or budesonide. Further, other 
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medications such as salmeterol, formoterol, albuterol, or levalbuterol can also be used to treat 
these conditions in conjunction with ICS.2 
It is known that oral corticosteroids (OCS) impair insulin action, which can lead to 
hyperglycemia.4 Further, both serum glucose and glycated hemoglobin (HbA1c) are used to 
distinguish between a disease state where a person has DM, is pre-diabetic, and when a person 
does not have DM. These same levels are also used to monitor the disease state once a person 
has a diagnosis of DM.2 Since it is known that OCS can impact DM onset and control by 
affecting blood glucose levels, it stands to reason that inhaled corticosteroids could have a 
similar effect on insulin action. Given the rise in people being diagnosed with a condition 
requiring ICS, and that many people are facing rising risk factors for DM, due to the obesity 
epidemic in the United States5, is close glucose monitoring needed to prevent incidence and 
progression of DM in those using ICS? 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not inhaled 
corticosteroids (ICS) cause an increased risk for developing or worsening a patient’s diabetes 
mellitus (DM). 
METHODS 
 The studies selected for this review focused on patients over the age of 18 who presented 
using ICS or with indications for use of ICS. This class of drug also served as the interventions 
for the studies and was compared to placebo and/or other medications. The outcomes measured 
were progression to diabetes, change in anti-diabetic medication, or use of insulin. 
 Three types of studies were included in the review. One was a new-user cohort of patients 
and a nested case-control analysis. Next, a randomized control trial (RCT) was used. Finally, a 
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prospective randomized, double blind, double dummy, placebo-controlled, crossover 
investigation was utilized for the review. 
 All the studies for this review were found using the Ovid MEDLINE, PubMed, and 
Cochrane databases.  The studies are all English language primary studies published between 
1993 and 2010.  The key words used in the searches were inhaled corticosteroids and diabetes. 
The articles were selected based on the following inclusion criteria: first, the studies were either 
RCTs or another form of primary research; second, the outcomes of the trials were found to be 
patient oriented evidence that matters (POEMS); third, the articles had been published in peer-
reviewed journals; finally, the articles had not been used in a previously published systematic 
review (SR) or meta-analysis (MA). If the study had disease-oriented evidence (DOE) only, or 
had previously been used in an SR or MA, the study was excluded from this review. From these 
criteria, three studies were chosen for review: The effect of an inhaled corticosteroid on glucose 
control in type 2 diabetes (Faul et al)1; Effect of eight months of inhaled beclomethasone 
dipropionate and budesonide on carbohydrate metabolism in adults with asthma (Kiviranta et 
al)6; and Inhaled corticosteroids and the risks of diabetes onset and progression (Suissa et al)7. 
 The studies chosen for this review used the following statistics in reporting their data: 
mean change from baseline; p-value; relative risk increase; absolute risk increase; number 
needed to harm; median change from baseline; rate ratios; and confidence intervals. 
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Table 1: Table of Demographics and characteristics of included studies     
Study Type # Pts Age (yrs) 
Inclusion 
criteria 
Exclusion 
Criteria W/D Interventions 
Faul, 
2009 
Prospective 
randomized, 
double-
blind, 
double-
dummy 
placebo-
controlled, 
crossover 
investigation 
14 52-76 
≥18 yo, 
DM2 by 
fasting 
plasma 
glucose 
>126 mg/dl, 
physician dx 
either 
asthma or 
COPD 
Tobacco use w/i 
6mo; 
exacerbation of 
asthma/COPD 
w/i 3 mo; current 
insulin use; use 
of systemic 
corticosteroids or 
ICS, leukotriene 
receptor 
antagonists, or 
theophylline w/i 
1mo; inability to 
read/complete 
diary card; 
inability to 
perform 
PEF/spirometery; 
inability to use 
MDI with spacer 
2 
Inhaled 
fluticasone 
propionate (440 
µg twice daily) 
and oral 
montelukast 
(10mg/day) 
Kiviranta, 
1993 RCT 
30 (15 
with 
asthma, 
15 
control) 
18-56 
≥18yo, 
unstable 
asthma 
Glucocorticoid 
use 0 
Inhaled 
beclomethasone 
dipropionate 
and budesonide 
Suissa, 
2010 
New-user 
cohort of 
patients and 
a nested 
case-control 
analysis 
388,584 66 (±15) 
Dispensed 
≥3 
prescriptions 
for 
respiratory 
medications 
in a 1-year 
period 
Diagnosis of 
diabetes or 
dispensed a 
prescription for 
an anti-diabetic 
drug 
0 
Inhaled 
corticosteroids 
of any type 
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OUTCOMES MEASURED 
 The studies focused on various aspects of monitoring blood sugars and medication use as 
related to the diagnosis and treatment of DM. The Faul et al study measured glucose control in 
type 2 diabetic patients to avoid diabetic treatment changes using HbA1c levels.1 Kiviranta et al 
measured insulin resistance possibly leading to a diagnosis of diabetes and glucose intolerance 
possibly leading to a diagnosis of diabetes. This was done using the oral glucose tolerance test 
(OGTT).6 Finally, Suissa et al measured incidence of diabetes and progression in severity of 
diabetes. Since the study was a nested case-control analysis, it measured when patients were 
advanced in their DM treatment or when anti-diabetic medication was initiated according to the 
patient’s medical record.7 
RESULTS 
Faul et al used ten people from an outpatient setting with concomitant DM and asthma or 
COPD broken into two groups. One received inhaled fluticasone propionate and oral placebo, the 
other oral montelukast and inhaled placebo for six weeks at the end of which, the groups were 
crossed over to the other treatment regimen for another 6 weeks. The inclusion criteria were: 18 
years of age or older; type 2 DM; and a physician diagnosis of asthma or COPD on their medical 
records. Patients were excluded if they used tobacco within 6 months of enrollment in the trial, 
had an exacerbation of asthma/COPD within 3 months of the trial’s start, were currently using 
insulin, used corticosteroids or leukotriene receptor antagonists or theophylline within 1 month 
of the trial, had an inability to read or write well enough to fill out the diary, were unable to 
perform pulmonary function tests, or had an inability to use a metered dose inhaler (MDI) with 
spacer.1 ICS effect on glucose control was evaluated by this study as shown in Table 2. The 
primary outcome measured was the difference between patients’ HbA1c levels after six weeks of 
Luttjohann, ICS and DM Page 6 
fluticasone and when they had been on oral montelukast for six weeks. The second outcome 
measured was the change from baseline of a patient after each therapy. Mean change from 
baseline was +0.11 with fluticasone (SD 0.17). 20% of patients experienced an increase in 
HbA1c with oral montelukast while 70% of patients experienced some increase in HbA1c with 
fluticasone. The absolute risk increase was 50% with a number needed to harm of 2. While the 
difference in changes of HbA1c were not statistically significant (p-value <0.025), the 
researchers highly recommend close monitoring of type 2 diabetes patients needing inhaled 
steroid treatment due to the large percentage of trial patients who experienced some change in 
their HbA1c levels. Also prompting the recommendation was the low number needed to harm 
(NNH), which, in this study, refers to the number of patients who experienced a change in their 
HbA1c while taking ICS. Two patients were removed for non-compliance before randomization 
of the subjects. Additionally, two patients were removed for non-compliance after the trial began, 
one from each arm of the trial, so their data were simply excluded since the number of subjects 
in both arms remained the same. Phone contact was made weekly with the subjects to ensure 
their compliance with treatment throughout the trial.1 
Table 2: Faul - Higher HgbA1c after 6 weeks of therapy1 
CERa EERb RRIc ARId NNHe p-value 
20% 70% 2.5 50% 2 <0.025 
a = CER (Control Event Rate) = % of patients with higher HbA1c on oral montelukast 
b = EER (Experimental Event Rate) = % of patients with higher HbA1c on inhaled 
fluticasone propionate 
c = RRI (Relative Risk Increase), d = ARI (Absolute Risk Increase), e = NNH (Number 
Needed to Harm) 
 
Kiviranta et al studied the effects on carbohydrate metabolism in adults of both inhaled 
beclomethasone dipropionate and budesonide at low doses for five months, followed by high 
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doses of these drugs for three months. Fifteen individuals with unstable asthma were matched 
with fifteen healthy controls for the study. Patients were included if they had currently unstable 
asthma, and excluded if they had a previous history of glucocorticoid use. This study primarily 
evaluated the control of asthma, but as a secondary outcome, blood glucose and insulin 
sensitivity were also measured.6 This aspect of the study was measured using median change 
from the baseline blood glucose and serum insulin levels of each patient. At the onset of the 
study, patients were admitted to a hospital to establish a baseline for measuring their blood 
glucose and serum insulin levels. Table 3 shows that the median fasting blood glucose decreased 
from 4.8 mmol/L to 4.5 mmol/L at 1 month, rose to an average of 4.8 mmol/L at 5 months, and 
dropped to 4.7 mmol/L at 8 months (p <0.05). Median change from baseline with fasting serum 
insulin levels increased from 8mU/L to 10 mU/L with beclomethasone and decreased from 9 
mU/L to 7 mU/L with budesonide at 1 month. Values for both medications leveled off around 8 
mU/L for the remaining reported values at 5 and 8 months (beclomethasone – p <0.005 and 
budesonide – p <0.01). The reported statistics could not be converted to dichotomous data.6 No 
mention was made of how the compliance of patients was followed within the article. 
Table 3: Kiviranta – Median change in blood glucose and serum insulin from baselines6 
  
Baseline 1 Month 5 Months 8 Months 
 BDPa BUDb BDP BUD BDP BUD BDP BUD 
 Fasting 
Blood 
Glucosec 
4.8 4.8 4.5 4.5 4.7 4.9 4.7 4.7 
 (4.6-
5.4) 
(4.2-
5.3) 
(4.1-
4.9) 
(4.0-
5.4) 
(4.3-
5.6) 
(4.2-
5.3) 
(4.5-
5.0) 
(4.1-
5.4) 
 Fasting 
Serum 
Insulind 
8 9 10 7 8 8 7 8 
 
(6-15) (6-22) (5-15) (5-20) (4-35) (5-24) (5-10) (6-25)   
c,d = p-values: Fasting Blood Glucose <0.05, Fasting Serum Insulin <0.05 (BDP) and <0.01 
(BUD) 
Ranges in parentheses, a = BUD = Budesonide, b = BDP = Beclomethasone Dipropionate 
Fasting Blood Glucose in mmol/L, Fasting Serum Insulin in mU/L     
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Suissa et al formed a cohort of 388, 584 adult patients who were treated in Quebec’s 
health system for respiratory disease. These patients were followed using data gleaned from the 
records of patients from health insurance databases. The patients were studied until the year 2007, 
or until they experienced diabetes onset/progression. The authors of the study formed a cohort of 
people who had received a prescription for medication for a respiratory condition at any point 
during a one-year period. Patients were excluded from selection if they had a diagnosis of 
diabetes or had taken anti-diabetic medication before the beginning of the study. Once patients 
had progressed to the point of diabetes, those patients who were given a prescription for an anti-
diabetic medication during the period of study were grouped into a sub-cohort. Patients that were 
given insulin as their first anti-diabetic medication were excluded from this sub-cohort. Ten 
random records matched for age to the patients of interest in the study were selected to serve as 
controls for each case followed by the study.7 The study focused on whether or not ICS use 
would cause DM onset or speed progression to insulin use in patients with DM. As Table 4 
shows, Dichotomous data were not presented, but rather rate ratios were calculated for incidence 
of diabetes (34%) and progression from oral hypoglycemic agents to insulin (34%). The 
increased rate of incidence of diabetes was 34% (Rate Ratio of 1.34) with a 95% confidence 
interval (CI) of 1.29-1.39. Oral hypoglycemic to insulin progression was increased at a rate of 
34% (Rate Ratio of 1.34) as well, with a 95% CI of 1.17-1.53.7 Since the study was done only 
using medical records, there was no way of ascertaining compliance during the time period 
studied. 
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Table 4: Suissa – Rate Increase in Incidence and Progression of DM with ICS use7 
  Rate Increase Rate Ratio 95% CI 
  Incidencea 34% 1.34 1.29-1.39 
  Progressionb 34% 1.34 1.17-1.53 
  a = Incidence refers to new incidence of DM 
b = Progression refers to change from oral anti-diabetes medication to insulin 
 
Neither the Faul el al, nor the Kiviranta et al trials had any adverse effects reported 
during their studies. Suissa et al did not report on adverse effects in their nested case-control 
study because the data was collected purely from medical records, making it difficult to directly 
link any potential adverse effects to a single intervention.7  
DISCUSSION 
 ICS are widely used to treat asthma and COPD.7 ICS are first-line treatments for 
persistent asthma and are given to any age patient.8 While used for COPD, ICS are only useful in 
limited situations when a patient has frequent exacerbations and in those cases are prescribed in 
high doses.9 “ICS have been shown to have systemic effects, but their effect on glucose 
metabolism in patients with type 2 diabetes has not been well defined. Although considered a 
safe therapy, there are concerns about the systemic effects of ICS.”1(p14) OCS have clearly been 
shown to cause an increased risk of DM, and since ICS are inhaled versions of the same class of 
drugs, albeit with a different delivery, a similar set of reactions may occur with their use, 
prompting the concerns about systemic effects. 
 The studies by Faul et al and Kiviranta were limited in size with ten and thirty subjects 
respectively. Faul et al were limited in the length of time patients were treated with fluticasone in 
their study. The 6-week period of treatment was shorter than may have been needed to see the 
full effects of the medication, since the study measured HbA1c and red blood cells have a half-
life of sixty days. This could have affected the validity of measuring the effects of the fluticasone 
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treatment using HbA1c.1 
CONCLUSION 
Faul et al concluded that glucose control was affected by therapy with ICS, but to a 
degree smaller than would usually be clinically relevant. However, since the diseases are all 
increasing in prevalence, initiating a patient on ICS should prompt the clinician to consider 
monitoring his or her blood glucose levels more closely than otherwise might be needed, 
especially if the patient is diabetic.1 Kiviranta et al determined that an early decrease in insulin 
resistance occurs, but with prolonged therapy, a slight decrease in insulin sensitivity prevails.6 
Suissa et al related high doses of ICS to an increased risk of incidence of DM.7 Also, patients 
with DM were more likely to progress to needing treatment with insulin.7 
The evidence demonstrates that receiving inhaled corticosteroids increases a patient’s risk 
for developing DM or worsening a patient’s existing DM. The risk is small according to two of 
the three studies, which leads to the conclusion that while the risk exists, it should not preclude 
initiation of treatment, nor prompt discontinuation of treatment. Close monitoring, however, is 
strongly supported by the evidence within the studies analyzed.  
Two of the three studies did not strongly differentiate between asthma and COPD, so 
disease specific studies for both asthma and COPD would be excellent areas for further study. 
Since the dosing and length of time a person is exposed to an ICS is different between the two 
diseases, studying each disease separately may yield different conclusions from when they were 
combined.8, 9 Also, the weight of patients was not factored into the calculations done by the 
studies. While this is not directly linked to either COPD or asthma, it is related to an increased 
risk for DM. Further, obese patients may have difficulty breathing due to their excess weight, 
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which may worsen coexisting asthma or COPD. 10 It therefore bears further research to 
specifically evaluate obese patients using ICS. Lastly, since the peak age of asthma onset is 3 
years old, 8 it would be of benefit to study the effects of ICS use in children and adolescents. In 
the studies used for this review, only adults were considered. In addition, long term use of ICS in 
patients who have reached adult age and have used an ICS continuously since childhood or 
adolescence would give insight into the potential long-term risks for DM onset or progression of 
the most common population to have prolonged ICS exposure.2 
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